ISSN: 2161-1165

Epidemiology: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Epidemiology (Sunnyvale) 2019, Vol 9(2): 375
  • DOI: 10.4172/2161-1165.1000375

A Novel Tool to Evaluate the Accuracy of Predicting Survival and Guiding Lung Transplantation in Cystic Fibrosis

Aasthaa Bansal1*, Nicole Mayer-Hamblett2,3, Christopher H Goss4, Lingtak N. Chan1 and Patrick J. Heagerty5
1Department of Pharmacy, University of Washington, Seattle WA, USA
2Departments of Pediatrics and Biostatistics, University of Washington, Seattle, WA, USA
3Seattle Children’s Research Institute, Seattle, WA, USA
4Division of Pulmonary and Critical Care Medicine, Department of Medicine and Pediatrics, University of Washington, Seattle WA, USA
5Department of Biostatistics, University of Washington, Seattle WA, USA
*Corresponding Author : Aasthaa Bansal, The Comparative Health Outcomes, Policy, and Economic (CHOICE) Institute School of Pharmacy, University of Washington, Box 357630, 1959 NE Pacific Ave, H-375B Seattle, WA, USA, 98195, USA, Tel: +1 (206) 427-5448 , Email: abansal@uw.edu

Received Date: May 25, 2019 / Accepted Date: Jun 08, 2019 / Published Date: Jun 17, 2019

Abstract

Background: Effective transplantation recommendations in cystic fibrosis (CF) require accurate survival predictions, so that high-risk patients may be prioritized for transplantation. In practice, decisions about transplantation are made dynamically, using routinely updated assessments. We present a novel tool for evaluating risk prediction models that, unlike traditional methods, captures classification accuracy in identifying high-risk patients in a dynamic fashion.

Methods: Predicted risk is used as a score to rank incident deaths versus patients who survive, with the goal of ranking the deaths higher. The mean rank across deaths at a given time measures time-specific predictive accuracy; when assessed over time, it reflects time-varying accuracy.

Results: Applying this approach to CF Registry data on patients followed from 1993-2011 we show that traditional methods do not capture the performance of models used dynamically in the clinical setting. Previously proposed multivariate risk scores perform no better than forced expiratory volume in 1 second as a percentage of predicted normal (FEV1%) alone. Despite its value for survival prediction, FEV1% has a low sensitivity of 45% over time (for fixed specificity of 95%), leaving room for improvement in prediction. Finally, prediction accuracy with annually-updated FEV1% shows minor differences compared to FEV1% updated every 2 years, which may have clinical implications regarding the optimal frequency of updating clinical information.

Conclusions: It is imperative to continue to develop models that accurately predict survival in CF. Our proposed approach can serve as the basis for evaluating the predictive ability of these models by better accounting for their dynamic clinical use.

Keywords: Cystic fibrosis; Lung transplantation; Survival; Risk prediction; Classification accuracy

Citation: Bansal A, Mayer-Hamblett N, Goss CG, Chan LN, Heagerty PJ (2019) A Novel Tool to Evaluate the Accuracy of Predicting Survival and Guiding Lung Transplantation in Cystic Fibrosis. Epidemiology (Sunnyvale) 9:375 Doi: 10.4172/2161-1165.1000375

Copyright: © 2019 Bansal A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top